propranolol and Kahler Disease

propranolol has been researched along with Kahler Disease in 5 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research

Studies (5)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Beta-adrenergically Mediated Gene Expression (Change From Baseline)

Expression (up or down regulation) of genes involved in the stress response can be modulated through the beta-adrenergic pathway. The log2 RNA abundance is a means to normalize results to determine whether a gene is up regulated (value greater than 1) or down regulated (value less than 1). Differential change in log2 RNA abundance is defined by the fold change (FC) as log2FC=Log2(B)-Log2(A). Logarithmic measures are unitless. The change in the measure between two time points determines whether a gene has up-or down-regulated. (NCT02420223)
Timeframe: Baseline (Pre-Transplant); 4 weeks post-transplant

Number of Participants Diagnosed With Culture-positive Infection or Neutropenic Fever Greater Than 100.4 Degrees Fahrenheit

This measure is the number of subjects diagnosed with culture-positive infection or neutropenic fever greater than 100.4 degrees Fahrenheit. (NCT02420223)
Timeframe: Up to 100 days after transplant

Number of Subjects Experiencing Engraftment Syndrome as a Function of Beta-blocker Administration

Number of subjects experiencing any of: fever, diarrhea or rash requiring steroid intervention within 48 hours before or after neutrophil recovery. (NCT02420223)
Timeframe: 4 weeks

Time (Days) to Neutrophil Engraftment

This measure is the mean time to the beginning of three consecutive days where the neutrophil count (absolute neutrophil count) was 500 cells/mm^3 (0.5 x 10^9/L) or greater. (NCT02420223)
Timeframe: 4 weeks after transplant

Time (Days) to Platelet Engraftment

This measure is the mean time to the beginning of three consecutive days where the platelet count is at least 20,000/mm^3 (20 x 10^9/L) unsupported by a platelet transfusion. (NCT02420223)
Timeframe: 4 weeks

Number of Participants With Myeloma Response as a Function of Beta-blocker Administration

This measure is the number of participants experiencing a response defined by the International Uniform Response Criteria as: very good partial response (VGPR) or better (near complete response (nCR), complete response (CR), and stringent CR (sCR) according to at day 100 post-Hematopoietic Cell Transplant. (NCT02420223)
Timeframe: 100 days after transplant

Patient-reported Depression and Anxiety Scores

This measure will be assessed using the Hospital Anxiety and Depression Scale (HADS). The HADS scale includes fourteen 4-response Likert-scale questions graded 0 to 3. Seven questions are specific to depression; 7 questions are specific to anxiety. The score is the total of the responses in their respective categories. Lower scores indicated less depression and/or anxiety. Scores 0-7 indicate normal status; scores 8-10 suggest borderline abnormal status; and scores 11-21 indicate abnormal status. Only anxiety scores are presented. (NCT02420223)
Timeframe: Baseline and 4 weeks

Trials

1 trial available for propranolol and Kahler Disease

Other Studies

4 other studies available for propranolol and Kahler Disease